Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Medication Guide

Mirtazapine

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Transdermal ointment Multiple FDA labelers Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts
Reference refreshed
Aug 6, 2026, 7:47 p.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
Aug 6, 2026, 7:47 p.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
Aug 6, 2026, 7:49 p.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
Illustration placeholder
Mirtazapine

Mirtazapine

Drug type: Generic ingredient • Branded profile • FDA branded products available

Both Transdermal ointment Rx required 100% reference complete

Species: Both

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Mirtazapine

For body weight gain in cats with a history of weight loss. Species commonly shown: Both, Cat.

Generic name
Mirtazapine
Brand names
Mirataz®, AX Pharmaceutical Corp, Mirataz, Mirtazapine Anhydrous
Manufacturer
Multiple FDA labelers
Species
Both, Cat
Dosage forms
Transdermal ointment
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Mirataz® AX Pharmaceutical Corp Mirataz Mirtazapine Anhydrous
Dosage forms
Transdermal ointment

Indications / Uses

For body weight gain in cats with a history of weight loss.

Side Effects

Top reported reactions (openFDA): Death by euthanasia, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Anorexia, Decreased appetite, Diarrhoea.

FAQ

Both, Cat

Yes. Roxee shows this as prescription-only.

Transdermal ointment

Related Conditions

Pica Weight loss

Source Transparency

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For body weight gain in cats with a history of weight loss.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • wobbly/unsteady walking (1 reports)
  • Loss of appetite (1 reports)
  • Blood in urine (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?

Next actions

Talk to a Vet / Find a Vet Near You Save to pet meds Share page Review report evidence
Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Mirtazapine; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2026-US-003268
Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 27 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2026-US-003268
Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2026-US-003268
Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Unsteady walking (ataxia) (1 reports), Loss of appetite (1 reports), Blood in urine (1 reports), Bladder distension (1 reports), Bilirubinuria (1 reports)

Body systems represented Signal grouping

Digestive (1), Skin & allergy (1), Neurologic (1), Behavior (2)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Cat (21 reports), Dog (11 reports)

Breed metadata in reports Metadata only

Domestic Shorthair (4), Domestic Longhair (1), American Shorthair (1), Dalmatian (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Mirtazapine fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

wobbly/unsteady walking, Loss of appetite, Blood in urine

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Mirtazapine brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.
Vet source depth
  1. openFDA case USA-USFDACVM-2026-US-003268 · adverse_reaction · adverse reactions
  2. FDA application profile · official_label · quick facts
  3. Medication usage source · fda_animal_drugs · quick facts
  4. FOI · document · documents
  5. SPL · document · documents
  6. Structured Product Label · document · documents
  7. Structured Product Label · document · documents
  8. Structured Product Label · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: February 12, 2026, 10:44 PM UTC

Sources:
Safety & side effects

Side effects to monitor:

  • wobbly/unsteady walking
  • Loss of appetite
  • Blood in urine

Most reported reactions:

  • Unsteady walking (ataxia) (1 reports)
  • Loss of appetite (1 reports)
  • Blood in urine (1 reports)
Explore reported case details

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species
Cat
Indication / use
For body weight gain in cats with a history of weight loss.
Form / route / dose
Form: Transdermal ointment
Route: Topical (transdermal)
Confirm product label and patient-specific plan.
Warnings
No structured warnings linked yet.
Adverse-event caveat
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Source docs

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA labelers
Form: Transdermal ointment
Identifiers:
NADA: 141481 NDC Package: 17033-060-05 NDC Package: 62157-466-01 NDC Package: 62157-506-01 NDC Package: 73377-003-01 NDC Package: 73377-090-01 NDC Package: 73377-090-02 NDC Package: 73377-090-04 NDC Package: 86032-071-01 NDC Product: 17033 NDC Product: 62157 NDC Product: 73377 NDC Product: 86032
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Stored reports
50
Matching reports
3
Active filters
2
Selected filters
Reaction: Decreased appetite Clear Body system: Neurologic Clear
Reset
Drill into common report signals
Lethargy (see also Central nervous system depression in Neurological) (14) Not eating (13) Lack of efficacy - NOS (10) Decreased appetite (9) Other (48) Digestive (24) Neurologic (15) Effectiveness (11)
Showing up to 50 matching reports.

USA-USFDACVM-2026-US-012224

Received 2026-03-13 · MSK · MSK

Non-serious
Species
Cat
Breed
Domestic Shorthair
Size / weight
Under 10 lb (3 Kilogram)
Age
8+ years (12.5 Year)
Sex
Female Neutered
Region
USA
Reactions
Tongue disorder NOSTongue ulcerationDroolingUnwellTracheal and laryngeal disorder NOSCrustDecreased appetiteLaryngeal oedemaCoughHead tilt - neurological disorder (see also Head tilt - ear disorder)Swallowing disorder NOSLocal swelling (not application site)Lethargy (see also Central nervous system depression in Neurological)Nasal dischargeMalaiseDehydrationOcular discharge
Body systems
OtherDigestiveNeurologicSkin & allergy
Outcomes
Recovered/Normal

USA-USFDACVM-2026-US-011648

Received 2026-03-10 · MSK · MSK

Serious
Species
Cat
Breed
Domestic Shorthair
Size / weight
10-24 lb (5.126 Kilogram)
Age
4-7 years (5 Year)
Sex
Female Neutered
Region
USA
Reactions
Emesis (multiple)Weight lossLethargy (see also Central nervous system depression in Neurological)Blood in vomitAbnormal ultrasound findingWeaknessDecreased appetiteINEFFECTIVE, ANTIEMETICDigestive tract disorder NOS
Body systems
DigestiveOtherNeurologic
Outcomes
Ongoing

USA-USFDACVM-2025-US-068234

Received 2025-11-12 · MSK · MSK

Serious
Species
Cat
Breed
Cat (unknown)
Sex
Mixed Unknown
Region
USA
Reactions
DeathHaematocheziaDecreased appetiteRegurgitationLethargy (see also Central nervous system depression in Neurological)DiarrhoeaDeath by euthanasia
Body systems
OtherDigestiveNeurologic
Outcomes
DiedEuthanizedOutcome Unknown

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
27
Species represented
2
Grouped by Body System
Digestive (1) · Loss of appetite Skin & allergy (1) · Alopecia local Neurologic (1) · Unsteady walking (ataxia) Behavior (2) · Behavioral disorder (unspecified), Aggression Other (27) · Blood in urine, Bladder distension, Bilirubinuria
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Neurologic 1 Cat 1
Digestive 1 Dog 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Dog 1
Behavior 1 Dog 1
Other 1 Cat 1
Other 1 Cat 1

Species coverage: Cat (21) Dog (11)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Cat Serious - 1
Digestive Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Behavior Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Non-serious - 1
Other Cat Non-serious - 1
Other Cat Non-serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Skin & allergy Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Behavior Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Non-serious - 1
Other Dog Serious - 1
Source metadata:

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

Mirataz® SPL · SPL Mirtazapine Anhydrous SPL SPL · Structured Product Label Mirtazapine anhydrous SPL SPL · Structured Product Label

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

5

FOI

1

Mirataz®

SPL · SPL

Open original
FDA Structured Product Label

Mirataz®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Dechra Veterinary Products LLC
NADA
141-481
Status
RX
Form
Transdermal ointment
Route
Topical (transdermal)
Species
Cat
Composition / specifications
Each 1 g of Mirataz™ contains 20 mg of mirtazapine (2%).

Cats

Indication

For body weight gain in cats with a history of weight loss.

Dosage

Administer topically by applying a 1.5-inch ribbon of ointment (approximately 2 mg/cat) on the inner pinna of the cat’s ear once daily for 14 days.

Mirtazapine Anhydrous SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Mirtazapine Anhydrous. Use the source link for the full official labeling record.

Mirtazapine anhydrous SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Mirtazapine anhydrous. Use the source link for the full official labeling record.

Mirataz SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Mirataz. Use the source link for the full official labeling record.

AX Pharmaceutical Corp SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for AX Pharmaceutical Corp. Use the source link for the full official labeling record.

FOI Summary oN 141-481 Approved May 4, 2018.pdf

FOI · FOI

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: AX Pharmaceutical Corp Mirataz Mirtazapine Anhydrous Mirtazapine anhydrous
Manufacturer mapping: Multiple FDA labelers
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Cat
Rx/OTC: RX
Form/route: Transdermal ointment • Topical (transdermal)
Applications: NADA 141-481
NDC: Packages 17033-060-05 62157-466-01 73377-090-01 73377-090-02 73377-090-04 86032-071-01 • Products 17033 62157 73377 86032
Documents: 1 (FOI: 1) • SPL: 1 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 88 • Cat 200 • View
Case summaries: 50 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Explore
Related conditions: Pica Weight loss
Linked using: Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Top reaction signals
Unsteady walking (ataxia) (1) Loss of appetite (1) Blood in urine (1) Bladder distension (1) Bilirubinuria (1) Behavioral disorder (unspecified) (1) Basophilia (1) Azotaemia (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 141481 NDC Package: 17033-060-05 NDC Package: 62157-466-01 NDC Package: 62157-506-01 NDC Package: 73377-003-01 NDC Package: 73377-090-01 NDC Package: 73377-090-02 NDC Package: 73377-090-04 NDC Package: 86032-071-01 NDC Product: 17033 NDC Product: 62157 NDC Product: 73377 NDC Product: 86032
Package NDC Product NDC Form / Route Status
17033-060-05 17033 -
62157-466-01 62157 -
62157-506-01 62157 -
73377-003-01 73377 -
73377-090-01 73377 -
73377-090-02 73377 -
73377-090-04 73377 -
86032-071-01 86032 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • Mirtazapine Anhydrous SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Mirtazapine anhydrous SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Mirataz SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • AX Pharmaceutical Corp SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • FOI Summary oN 141-481 Approved May 4, 2018.pdf • FOI summary • Official • July 14, 2026
    FDA FOI summary for application 141481

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 124 Clinical 1 Manufacturer 0 Marketing 0
Current Field Facts
  • side_effects: Top reported reactions (openFDA): Death by euthanasia, Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Anorexia, Decreased a… (Clinical, 2026-04-11)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-08-06)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-08-05)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-08-04)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-08-03)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-08-02)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-08-01)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-07-31)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-07-30)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-07-29)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-07-28)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-07-27)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-07-26)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-07-25)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-07-25)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-07-22)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-07-22)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-07-22)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-07-20)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-07-19)
Recent Revisions
  • side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Mirataz®
RX
Mirtazapine
Transdermal ointment • Topical (transdermal)
Label highlights
Official documents
Dechra Veterinary Products LLC NADA 141-481 Approved Jul 14, 2026

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Cat
Composition / specifications
Each 1 g of Mirataz™ contains 20 mg of mirtazapine (2%).
Cats
Indication

For body weight gain in cats with a history of weight loss.

Dosage

Administer topically by applying a 1.5-inch ribbon of ointment (approximately 2 mg/cat) on the inner pinna of the cat’s ear once daily for 14 days.

Limitations

FDA page: Open in Animal Drugs @ FDA

Usage

For body weight gain in cats with a history of weight loss.

Source: FDA Animal Drugs @ FDA • Reference

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Loss of appetite (1) • Dog

Showing top 5 for Digestive.

Skin & allergy
Alopecia local (1) • Cat

Showing top 5 for Skin & allergy.

Neurologic
Unsteady walking (1) • Cat

Showing top 5 for Neurologic.

Behavior
Behavioral disorder (1) • Dog Aggression (1) • Dog

Showing top 5 for Behavior.

Other
Blood in urine (1) • Dog Bladder distension (1) • Cat Bilirubinuria (1) • Dog Basophilia (1) • Cat Azotaemia (1) • Cat
Show more (22)
Autoimmune disorder NOS (1) • Dog Ascites (1) • Cat Arthritis (1) • Cat Application site skin scaling (1) • Cat Application site reaction NOS (1) • Cat Anuria (1) • Cat Anaphylaxis (1) • Dog Anaemia NOS (1) • Cat Agonal breathing (1) • Dog Agitation (1) • Dog Adipsia (1) • Cat Acute renal failure (1) • Cat Active urine sediment (1) • Dog Accidental exposure (1) • Cat Abrasion (1) • Cat Abnormal ultrasound finding (1) • Cat Abnormal radiograph finding (1) • Cat Abnormal menace reflex test (1) • Cat Abnormal histology NOS (1) • Cat Abnormal cytology (1) • Cat Abdominal pain (1) • Cat Abdominal discomfort (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Male, 12 year, 4.536 kilogram • Drug: MSK, Tablet, Oral, Dose: 3.75 Milligram per dose, Frequency: 1 per day • Reactions: Lateral recumbency, Agonal breathing, Death • Outcome: Died

  • Report ID: USA-USFDACVM-2026-US-013917
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Male
  • Age: 12.00 Year
  • Weight: 4.536 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Tablet
  • Dose: 3.75 Milligram per dose
  • Frequency: 1 per day
Reactions Reported:
Lateral recumbency Agonal breathing Death
Outcomes: Died

Cat, Domestic Shorthair, Female, 24 year, 2.5 kilogram • Drug: MSK, Ointment, Transdermal, Dose: 0.75 Other per animal, Frequency: 24 per hour • Reactions: Lack of efficacy - NOS, Application site reaction NOS • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2026-US-014720
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 24.00 Year
  • Weight: 2.500 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Transdermal
  • Form: Ointment
  • Dose: 0.75 Other per animal
  • Frequency: 24 per hour
Reactions Reported:
Lack of efficacy - NOS Application site reaction NOS
Outcomes: Outcome Unknown

Cat, Domestic Longhair, Male, 10 year, 5.534 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Hyperglycaemia, Diarrhea, Watery diarrhoea, Inappetence, Elevated betahydroxybutyrate • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-013837
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Male
  • Age: 10.00 Year
  • Weight: 5.534 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Hyperglycaemia Diarrhea Watery diarrhoea Inappetence Elevated betahydroxybutyrate
Outcomes: Ongoing

Cat, American Shorthair, Female, 3.311 kilogram • Drug: MSK, Unknown • Reactions: Decreased appetite, Behavioral disorder (unspecified), Pulmonary oedema, Trouble breathing (dyspnea), Intentional misuse • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2026-US-012583
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Weight: 3.311 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Decreased appetite Behavioral disorder (unspecified) Pulmonary oedema Trouble breathing (dyspnea) Intentional misuse
Outcomes: Recovered/Normal

Cat, Domestic Shorthair, Male, 11 year, 6.26 kilogram • Drug: MSK, Unknown • Reactions: Not eating, Drooling, Hypoglycaemia, Hypotension, Abnormal ultrasound finding… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-012294
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 11.00 Year
  • Weight: 6.260 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Not eating Drooling Hypoglycaemia Hypotension Abnormal ultrasound finding Hiding Behavioral disorder (unspecified) Tiredness (lethargy) Hypothermia Dehydration Neutropenia Diarrhea Soft stool
Outcomes: Ongoing

Dog, Dalmatian, Male, 10 year, 36.741 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Agitation, Drooling, Febrile, Panting, Anaphylaxis… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-012695
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 10.00 Year
  • Weight: 36.741 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Agitation Drooling Febrile Panting Anaphylaxis Unwell Decreased appetite Urinary incontinence Vomiting Diarrhea Leukocytosis NOS Neutrophilia Lymphocytosis Monocytosis Elevated globulins Elevated serum alkaline phosphatase Anaemia NOS Elevated alanine aminotransferase Elevated C-reactive protein Aggression Urolithiasis Autoimmune disorder NOS Thrombocytopenia
Outcomes: Ongoing

Cat, Domestic Shorthair, Male, 10 year, 2.9 kilogram • Drug: MSK, Unknown • Reactions: Decreased appetite, Lack of efficacy - NOS, Weight loss • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2026-US-012574
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 10.00 Year
  • Weight: 2.900 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Decreased appetite Lack of efficacy - NOS Weight loss
Outcomes: Outcome Unknown

Cat, Domestic Shorthair, Female, 12.5 year, 3 kilogram • Drug: MSK, Unknown • Reactions: Tongue disorder NOS, Tongue ulceration, Drooling, Unwell, Tracheal and laryngeal disorder NOS… • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2026-US-012224
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 12.50 Year
  • Weight: 3.000 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Tongue disorder NOS Tongue ulceration Drooling Unwell Tracheal and laryngeal disorder NOS Crust Decreased appetite Laryngeal oedema Cough Head tilt - neurological disorder Swallowing disorder NOS Local swelling Tiredness (lethargy) Nasal discharge Malaise Dehydration Ocular discharge
Outcomes: Recovered/Normal

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.